Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation, recognizes the financial hardships of cancer patients when paying for medications.
Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation, recognizes the financial hardships of cancer patients when paying for medications.
Transcript
Are you hearing from patients who read about new treatments that could cure them of their cancer, but who are facing barriers to getting access to this care?
We do. Patients will call us, and we do have a copayment assistance foundation, we do have funding for some types of cancers. We do hear from the patients when they call us and we don’t have a fund open for their type of cancer and they are very frustrated. "My doctor says this is what I need to take and I can’t get it." Or the co-pay is $4000. Sometimes they get misinformation, too. They don’t fully understand what their out of pocket is versus what the full cost of the drug is.
We do hear from patients, "This is great, I heard this medication can save my life, but I can’t get it." We will refer them to the drug company but even that, I guess, patients have to qualify for those programs. Medicare patients are not usually eligible for manufacturer sponsored programs. So, it does leave a lot of gaps in coverage for a lot of people.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More